Oculis Holding AG (NASDAQ:OCS – Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $15.95, but opened at $15.60. Oculis shares last traded at $15.70, with a volume of 3,088 shares changing hands.
Analyst Ratings Changes
Separately, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Oculis in a research report on Wednesday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Oculis presently has a consensus rating of “Buy” and a consensus price target of $29.20.
View Our Latest Analysis on OCS
Oculis Price Performance
Oculis (NASDAQ:OCS – Get Free Report) last posted its quarterly earnings data on Tuesday, August 27th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.13). Oculis had a negative net margin of 7,679.05% and a negative return on equity of 61.33%. The business had revenue of $0.27 million during the quarter, compared to analyst estimates of $0.28 million. On average, equities research analysts expect that Oculis Holding AG will post -2.19 EPS for the current fiscal year.
About Oculis
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
See Also
- Five stocks we like better than Oculis
- What Are Dividend Contenders? Investing in Dividend Contenders
- Texas Roadhouse Stock Steering for New Highs This Year
- What are earnings reports?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Manufacturing Stocks Investing
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.